Neupogen: adverse event reports filed with FDA

7,128

reports as suspect product

0% of all reports · about 317 a year

66

reports, 12 months to June 2026

149 in the 12 months before

64.6%

marked serious by the reporter

32.6% across the class

14.9%

record death among outcomes, as reported

1,062 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Neupogen reports recording the termmedian drug in leukocyte growth factor

1. Off label useused for a purpose or in a way not on the label10.3%736
2. Bone painbone pain7.2%512
3. Deaththe patient died; cause not stated by this term7.1%507
4. Pyrexiafever6.1%432
5. Febrile neutropeniafever with low white blood cells5.8%415
6. Product storage errorthe product was stored wrongly5.7%408
7. Neutropenialow neutrophils, a type of white blood cell5.5%395
8. Fatiguetiredness4.7%335
9. White blood cell count decreasedlow white cell count4.5%319
10. Nauseafeeling sick4.4%315
11. Drug ineffectivethe medicine did not work as expected3.9%280
12. Dyspnoeashortness of breath3.9%275
13. Circumstance or information capable of leading to medication errora situation that could lead to a medication error3.5%253
14. Painpain, site not specified3%213
15. Back painback pain2.8%199
16. Diarrhoealoose or frequent stools2.7%193
17. Vomitingbeing sick2.7%189
18. Rashskin rash2.6%182
19. Hospitalisationadmission to hospital2.5%175
20. Headachehead pain2.4%169
21. Malaisegeneral feeling of being unwell2.4%168
22. Thrombocytopenialow platelets2.3%166
23. Arthralgiajoint pain2.2%158
24. Astheniaweakness or lack of energy2.2%156
25. Pneumonialung infection2.1%147
26. Anaemialow red blood cells2%144
27. Sepsisa severe body-wide response to infection2%144
28. Infectionan infection, type not specified2%141
29. Platelet count decreasedlow platelet count1.9%136
30. Chest painchest pain1.9%134

Top 30 of 949 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 7 drugs in the leukocyte growth factor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 109,309 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 62.6% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 7,128 reports.

Drugs most often listed in the same reports

Other products listed in reports where Neupogen is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the leukocyte growth factor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Neupogen as a suspect or interacting product; reports listing it only as a concomitant medication (7,974) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.